UEG Week 2026
October 17, 2026 - October 20, 2026
Barcelona, Spain
Nordic Bioscience will be attending UEG Week 2026 in Barcelona, Spain. The 4-day congress will take place from October 17-20 and unites experts on digestive health from all over the world.
Our team will present various presentations about how our biomarkers can be applied in gastrointestinal diseases. We invite you to take a look at the overview down below, and to come by during the UEG week. You can also reach out to us, if you are interested in scheduling a meeting with us.
Presentation overview
| Identifier | Presentation title | Session | Author | Presentation time & Location |
| PP1124 | Biomarkers of neutrophil and macrophage activity discriminate non-IBD from Crohn’s disease and associate with endoscopic disease activity | IBD (Including microscopic colitis) | Dr. Marta Sorokina Alexdóttir | Sunday, October 18, 09:00-18:00 – Hall 7 Poster area |
| PP1103 | Extracellular matrix biomarkers may aid in choice of advanced therapy sequencing to vedolizumab in patients with Crohn’s disease | IBD (including microscopic colitis) | Dr. Marta Sorokina Alexdóttir | Sunday, October 18, 09:00-18:00 – Hall 7 Poster area |
| MP0094 | Markers of ECM remodeling and wound healing are associated with fibrostenotic Crohn’s disease | Fibrosis in IBD | Dr. Letizia Satriano | Sunday, October 18, 09:00-18:00 – Hall 7 Poster stage 3 (10:48-10:54) |
| OP091 | Obefazimod targets MIR-124 to modulate consistantly inflammation and fibrosis across preclinical models | Molecular trajectories of disease and drug responses in IBD | Dr. Joachim Mortensen | Monday, October 19, 10:00-11:00 – Hall 7 Poster stage 3 (10:50-11:00) |
| MP0913 | CPA9-HNE, a novel biomarker of neutrophil activity is associated with transmural healing in pediatric Crohn’s disease – IMAGEKIDS STUDY | Understanding IBD: Translating science into care | Dr. Joachim Mortensen | Tuesday, October 20, 11:30-12:30 – Hall 7 Poster stage 2 (11:51-11:57) |
| MP0918 | Immune cell-driven fibrogenesis is fully suppressed by upadacitinib in a gastrointestinal Scar-in-a-Jar-model, quantified by translational biomarkers | Understanding IBD: Translating science into care | Thomai Tsapanou-Katranara | Tuesday, October 20, 11:30-12:30 – Hall 7 Poster stage (12:21-12:27) |
